A Safety & Efficacy Study of Treatment With AP1189 in Rheumatoid Arthritis Patients naïve to DMARD Treatment

NCT05516979 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

127

Enrollment

INDUSTRY

Sponsor class

Conditions

Rheumatoid Arthritis

Interventions

DRUG: 100 mg AP1189
DRUG: Placebo

Sponsor

SynAct Pharma Aps

Collaborators

[object Object]